The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient ... ingredient Companies such as Procter & Gamble and GSK ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

GSK has taken another step towards rebuilding ... in late-stage development as a chronic cough therapy. The big pharma needs to boost its pipeline as it is facing patent expiry in 2027 for HIV ...

Therapeutic area expertise motivated GSK to acquire Bellus Health and develop a new medicine for patients with refractory chronic cough ... agreements with Hansoh Pharma for novel ADCs in oncology.

Bearish flow noted in GSK (GSK) Pharma with 14,964 puts trading, or 17x expected. Most active are 11/1 weekly 37 puts and 11/1 weekly 38.5 calls, with total volume in those strikes near 19,700 ...

Leading MNCs have shown their presence The Indian market has seen entry from most of the Big Pharma players ... Piramal) in cough and cold preparations and gastro intestinals, GSK in anti ...

New Delhi: At least 6% cough syrup samples belonging to 54 Indian pharmaceutical manufacturers failed the mandatory quality test for export till October this year, according to government data.

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Less of the rapid pneumonia breathing; less of the fever, the sucking chest, the rattling cough, the blue lips ... the greatest achievements of modern medicine. Measles, for example, was killing ...

During the recession, pharmaceutical giant GlaxoSmithKline has exited the ... (COPD), which causes daily wheezing and a mucus-filled cough. Untreated asthma can also cause more than just physical ...